BIO - Bio-Rad Laboratories, Inc.
| Previous Close | 294.13 |
| Open | 293.49 |
| Bid | 293.68 x 800 |
| Ask | 293.98 x 1200 |
| Day's Range | 292.52 - 297.43 |
| 52 Week Range | 220.05 - 345.15 |
| Volume | 61,624 |
| Avg. Volume | 254,067 |
| Market Cap | 8.83B |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | 24.31 |
| EPS (TTM) | 12.10 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 357.50 |
- Insider Monkey•2 days ago
Is Bio-Rad Laboratories, Inc. (BIO) A Good Stock To Buy?
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Zacks•5 days ago
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid
Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
- Business Wire•7 days ago
Bio-Rad to Report First-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.
- Zacks•10 days ago
Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
The U.S. labor market is the major driver of the bull run, which is more than a decade old.
- American City Business Journals•12 days ago
FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year
A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BIO are favorable with net inflows of $183.01 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•13 days ago
Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
- Investor's Business Daily•13 days ago
Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
Stock futures: Zogenix plunged early Tuesday on FDA news, while GW Pharma stock rose and PhaseBio stock soared. Bio-Rad won an FDA approval, but shares were quiet near a buy point.
- Business Wire•14 days ago
Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.
- Zacks•19 days ago
Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm
The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.
- Business Wire•20 days ago
Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.
- American City Business Journals•20 days ago
Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies
Tesla last year awarded CEO Elon Musk a stock options package worth $2.28 billion — which works out to some 40,668 times more than what the company’s median worker earns in a year.
- Business Wire•20 days ago
Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.
- Zacks•23 days ago
Why Is Bio-Rad (BIO) Up 12.8% Since Last Earnings Report?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•26 days ago
Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•28 days ago
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"). As previously disclosed, the reason for the delay is the additional time needed by Bio-Rad to complete its year-end procedures, including its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018.
- PR Newswire•last month
GBT Reports Fourth Quarter and 2018 Results
Company Alignment on Long-term Strategic Agenda and Investment on Operation and Execution MONTEVIDEO, Uruguay , March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical ...
- Zacks•last month
Top Ranked Momentum Stocks to Buy for March 21st
Top Ranked Momentum Stocks to Buy for March 21st
- Zacks•last month
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.
- Zacks•last month
Looking for a Growth Stock? Why It is Time to Focus on Bio-Rad (BIO)
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Rad (BIO).
- Zacks•last month
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
- Zacks•last month
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
Stryker (SYK) makes a few lucrative acquisitions in recent times.
- Zacks•last month
HEXO Catches Eye: Stock Jumps 6.6%
HEXO saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Zacks•last month
Here is Why Growth Investors Should Buy Bio-Rad (BIO) Now
Bio-Rad (BIO) could produce exceptional returns because of its solid growth attributes.
